Advancing the Fight Against Serious Diseases

Partner with Proton Calibration Technologies (PCT) to advance the fight against cancer, introduce a new modality to ablate cardiac arrhythmias, and enable new applications for material science. Take the fight against cancer to the next level with PCT as we help proton centers reduce costs and improve patient outcomes for cancer patients around the world. Proton Computed Tomography (pCT) will also open a new market to proton therapy centers, enabling them to begin treating heart arrhythmia issues non-invasively — without surgery or anesthesia, and in a shorter time.

PCT is on a mission to commercialize the world’s fifth medical imaging modality. Early investors in X-ray CT and MRI did quite well. Here is your chance to be in on the next 3D patient imaging system. Furthermore, pCT will provide the material science community and material manufacturers with an important new tool.

Demand for a pCT solution in proton beam therapy (PBT) has been evident for many years. Most recently, interest in pCT has become a hot topic among the existing proton therapy centers. They realize that a breakthrough is required to surmount the reimbursement reductions for Medicare patients soon to be enacted in the Radiation Oncology – Alternative Payment Model. More cancer patients would be referred by physicians to proton therapy centers if the range uncertainty problem were solved. We have a system with great commercial potential at a time when demand for it is at an all-time high and continues to grow.

Proton-beam radiotherapy, used to treat solid tumors, can be much more highly targeted, with up to 6X less radiation reaching healthy tissue. This translates into a 92% reduction in the rate of secondary cancer as a result of radiation treatment and much less damage to surrounding tissue, improving patient survival and quality of life.

Proton beam therapy has been in use for 35 years, and it can treat most forms of pre-metastatic cancer. It is cleared by the FDA, and is reimbursed by public and private insurers around the world.

The PCT Difference

A Breakthrough Technology

PCT’s primary advantage is its algorithm. It has long been known that the sinogram algorithm used in X-ray CT will not work for pCT. A few attempts have been made to develop a new algorithm suitable for pCT over the past couple of decades. With PCT’s new patent-pending proprietary algorithm we have succeeded. Further, our algorithm works even with the limited energy resolution of the current generation of proton detectors. Our design does not require the use of contrast agents, etc. With the algorithm in place, it is now possible to design the pCT system, via mathematical modeling and CAD. We have conducted the required sensitivity analysis. At this point the pCT system design is a matter of advanced engineering of a suitable detector. PCT also has a set of improvements waiting to be deployed as the company grows. With each generation of our pCT system we will improve image quality and reduce the dose to the patient. We will also expand into treatment planning for carbon ion therapy centers. We have interest from the material science research centers to co-develop applications for pCT.

PCT will apply for FDA 510(k) De Novo Class II (diagnostic medical device) clearance. Following FDA clearance, PCT will apply for the medical device “CE Mark” to permit product sales and distribution in European countries.

The market requires an apples-to-apples comparison used to assure fidelity between planning and delivery; that is, we measure with protons and treat with protons. The use of protons rather than X-rays to produce an image results in adequate information to calculate the treatment plan for the patient prior to proton treatment and provides a direct determination of the proton relative stopping power (RSP) in the patient. Using the 3D RSP map, proton centers will be able to predict dose distributions with less than 1% range uncertainty. With pCT, clinics are able to have the Bragg Peak “scalpel” cut exactly where it should, hence the term “calibration”. Proximal and distal margins, used to account for uncertainties, may now be reduced and higher fractional doses may now be administered safely and confidently. Compared with previous pCT research and development efforts which focused on the detector, we have focused on the critical part, namely, the algorithm.

Cancer patients and their doctors often face agonizing trade-offs that must be made to balance the probability of a cure with future quality of life. Further, they must consider how close to critical organs they are willing to go and how high they will adjust the strength of the radiation dose to irradiate the solid tumor. Our technology can help provide the radiation oncologist with more options. The reduced uncertainty margins and more economical adaptive treatment plans are extremely valuable, streamlining workflow. Our pCT system provides a direct confirmation that the dose will be delivered as prescribed. Such confidence is a critical necessity from the healthcare providers’ perspective as the market moves into hypofractionated treatment and ablating the heart’s electrical nodes. In short, we both image and treat with protons. No other method can provide this apples-to-apples linkage.

As an investor, you will not only serve an important role in reducing the costs of healthcare for the two most devastating diseases – cardiovascular and cancer – you will catalyze an innovation to improve patient outcomes and enhance quality of life. With pCT, the annual global market for using proton therapy for cancer and heart arrhythmia is over $5B.

We are targeting proton therapy centers with commercially sourced PBT systems. Proton therapy has been on an exponential growth path for over 15 years. As of 2022 there are over 120 proton therapy centers worldwide and 85 under development, with over 360 treatment rooms in operation. By 2028, growth projections call for ~50 rooms per year to be added. The world market is projected to be ~750 total treatment rooms by 2028. Our pCT system can be easily retrofitted into an existing proton center room. Assuming that PCT can sell pCT to 70% of the total rooms, the pCT unit sales potential over the next 10 years will be over 500 treatment rooms.

Without pCT many proton centers are struggling financially – the centers have only one treatment modality – solid tumors. With reimbursement revenue under constant pressure and given the high capital acquisition costs and operating expenses, proton centers need a breakthrough to return to profitability.

PCT anticipates significant margins on sales of pCT units, and also plans to offer a fee-for-service model. With pCT, proton centers will return to profitable operation. This will be true for treating patients with cancer, certainly, and once PBT becomes first-line treatment for ablation of cardiac arrhythmias (VT and A-fib) the situation will improve dramatically. Contact us today to learn more about investment opportunities with Proton Calibration Technologies.

Provisional Patent for the pCT algorithm is filed with the United States Patent and Trademark Office (February 2022). Due to the complex physics and mathematical methods employed, PCT’s algorithm is not easy to duplicate. Anyone wishing to pursue an algorithmic solution must study this for a few years. As PCT is taking an entirely new approach to pCT the IP field is “wide open”. Review and analysis of the current patent and scientific literature shows that everyone working on pCT is trying to copy the X-ray CT approach, a paradigm which has failed for two decades.

Initial seed fundraising round is complete, next fundraising round is underway. At the next stage, PTC’s work will require detectors/electronics, proton beam time, then animal imaging. A novel application of pCT – proton beam ablation of cardiac arrhythmia – is emerging. Human clinical trials are currently underway, after successful trials with animals. Among targets for catheter based ablation, VT, and to some extent AF, have the lowest reported success rates.

The field of radiation oncology, in peer-reviewed journal articles, has established that range uncertainty is a major obstacle to growth for proton therapy. pCT solves range uncertainty. pCT is the technology that enables high doses to be safely given to a tumor over a shorter treatment schedule. This is key to profitability for a proton therapy cancer treatment center.

Proton Calibration Technologies logo


Proton Calibration Technologies
986 N. Cedar Cove Road
Hartselle, AL 35640

Market Size


Proton Therapy Centers Worldwide
PBT Treatment Rooms in Operation
Treatment Rooms Forecasted by 2028

Investment Opportunities

With PCT

Contact Proton Calibration Technologies to learn more about investment opportunities as we help cancer centers reduce costs and improve patient outcomes for cancer patients around the world.